Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Phase 2

Active, not recruiting

Conditions: Unresectable Alveolar Soft Part Sarcoma
Metastatic Alveolar Soft Part Sarcoma

Interventions: Drug: Atezolizumab
Procedure: Biospecimen Collection
Biological: Bevacizumab
Procedure: Computed Tomography

First Posted Date: 2017-05-05

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT03141684

Locations: 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 39 locations

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: NKTR-214
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Atezolizumab
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2017-05-03

Last Posted Date: 2023-03-10

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 162

Registration Number: NCT03138889

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇩🇪
Lungenklinik Hemer, Hemer, Germany
🇺🇸
Highlands Oncology Group, PA - North Hills, Fayetteville, Arkansas, United States

and more 35 locations

Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer

Phase 1

Active, not recruiting

Conditions: Rectal Neoplasms

Interventions: Drug: Atezolizumab
Drug: 5-FU based radio-chemotherapy

First Posted Date: 2017-04-25

Last Posted Date: 2024-02-23

Lead Sponsor: Grand Hôpital de Charleroi

Target Recruit Count: 54

Registration Number: NCT03127007

Locations: 🇧🇪
GHdC, Charleroi, Hainaut, Belgium
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
Hôpital Erasme, Brussels, Belgium

and more 2 locations

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Phase 2

Active, not recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Paclitaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2017-04-24

Last Posted Date: 2024-01-03

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 16

Registration Number: NCT03125928

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: Atezolizumab

First Posted Date: 2017-04-19

Last Posted Date: 2019-11-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT03120676

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 3 locations

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Phase 2

Terminated

Conditions: Metastatic Renal Cell Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Drug: Nivolumab
Drug: Atezolizumab
Drug: Pembrolizumab
Radiation: Radiation & immunotherapy

First Posted Date: 2017-04-14

Last Posted Date: 2021-09-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 6

Registration Number: NCT03115801

Locations: 🇺🇸
Weill Cornell Medicine - New York Presbyterian Hospital, New York, New York, United States

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Phase 2

Completed

Conditions: Appendix Adenocarcinoma
Rare Lesion
Skin Squamous Cell Carcinoma
Metastatic Malignant Neoplasm
Rare Neoplastic Syndrome
Locally Advanced Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
Metastatic Small Intestinal Adenocarcinoma
Refractory Malignant Neoplasm
Stage IV Small Intestinal Adenocarcinoma AJCC v8

Interventions: Drug: Atezolizumab
Drug: Cobimetinib

First Posted Date: 2017-04-11

Last Posted Date: 2024-04-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT03108131

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Atezolizumab

First Posted Date: 2017-04-05

Last Posted Date: 2023-05-24

Lead Sponsor: Alliance Foundation Trials, LLC.

Target Recruit Count: 64

Registration Number: NCT03102242

Locations: 🇺🇸
EMMC Cancer Care, Brewer, Maine, United States
🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸
Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States

and more 10 locations

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Gynecologic Neoplasms

Interventions: Drug: Atezolizumab
Drug: Rucaparib

First Posted Date: 2017-04-05

Last Posted Date: 2020-10-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT03101280

Locations: 🇪🇸
Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸
La Paz University Hospital, Madrid, Spain
🇫🇷
Centre Hospitalier Lyon Sud; Service d'Oncologie Médicale, Pierre Benite, France

and more 8 locations

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma
Locally Advanced
Unresectable

Interventions: Drug: Atezolizumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2017-03-28

Last Posted Date: 2023-12-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 32

Registration Number: NCT03093922

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy